Literature DB >> 26567158

Haploinsufficient loss of multiple 5q genes may fine-tune Wnt signaling in del(5q) therapy-related myeloid neoplasms.

Angela Stoddart1, Joy Nakitandwe2, Shann-Ching Chen3, James R Downing2, Michelle M Le Beau4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26567158      PMCID： PMC4692148          DOI： 10.1182/blood-2015-10-673228

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  11 in total

1.  Gene expression profiling of CD34+ cells in patients with the 5q- syndrome.

Authors:  Jacqueline Boultwood; Andrea Pellagatti; Helen Cattan; Charles H Lawrie; Aristoteles Giagounidis; Luca Malcovati; Matteo G Della Porta; Martin Jädersten; Sally Killick; Carrie Fidler; Mario Cazzola; Eva Hellström-Lindberg; James S Wainscoat
Journal:  Br J Haematol       Date:  2007-10-03       Impact factor: 6.998

2.  Glycogen synthase kinase-3 is an in vivo regulator of hematopoietic stem cell repopulation.

Authors:  Jennifer J Trowbridge; Anargyros Xenocostas; Randall T Moon; Mickie Bhatia
Journal:  Nat Med       Date:  2005-12-11       Impact factor: 53.440

3.  Downregulation but lack of promoter hypermethylation or somatic mutations of the potential tumor suppressor CXXC5 in MDS and AML with deletion 5q.

Authors:  Marianne B Treppendahl; Lars Möllgård; Eva Hellström-Lindberg; Paul Cloos; Kirsten Grønbaek
Journal:  Eur J Haematol       Date:  2013-01-20       Impact factor: 2.997

4.  Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis.

Authors:  L Ysebaert; G Chicanne; C Demur; F De Toni; N Prade-Houdellier; J-B Ruidavets; V Mansat-De Mas; F Rigal-Huguet; G Laurent; B Payrastre; S Manenti; C Racaud-Sultan
Journal:  Leukemia       Date:  2006-05-11       Impact factor: 11.528

5.  Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series.

Authors:  Sonali M Smith; Michelle M Le Beau; Dezheng Huo; Theodore Karrison; Ronald M Sobecks; John Anastasi; James W Vardiman; Janet D Rowley; Richard A Larson
Journal:  Blood       Date:  2003-03-06       Impact factor: 22.113

6.  Haploinsufficiency of del(5q) genes, Egr1 and Apc, cooperate with Tp53 loss to induce acute myeloid leukemia in mice.

Authors:  Angela Stoddart; Anthony A Fernald; Jianghong Wang; Elizabeth M Davis; Theodore Karrison; John Anastasi; Michelle M Le Beau
Journal:  Blood       Date:  2013-12-31       Impact factor: 22.113

Review 7.  Wnt-related molecules and signaling pathway equilibrium in hematopoiesis.

Authors:  Sachin Malhotra; Paul W Kincade
Journal:  Cell Stem Cell       Date:  2009-01-09       Impact factor: 24.633

8.  Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS.

Authors:  Rebekka K Schneider; Vera Ademà; Dirk Heckl; Marcus Järås; Mar Mallo; Allegra M Lord; Lisa P Chu; Marie E McConkey; Rafael Kramann; Ann Mullally; Rafael Bejar; Francesc Solé; Benjamin L Ebert
Journal:  Cancer Cell       Date:  2014-09-18       Impact factor: 31.743

9.  Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia.

Authors:  Andrea Kühnl; Peter J M Valk; Mathijs A Sanders; Adam Ivey; Robert K Hills; Ken I Mills; Rosemary E Gale; Martin F Kaiser; Richard Dillon; Melanie Joannides; Amanda Gilkes; Torsten Haferlach; Susanne Schnittger; Estelle Duprez; David C Linch; Ruud Delwel; Bob Löwenberg; Claudia D Baldus; Ellen Solomon; Alan K Burnett; David Grimwade
Journal:  Blood       Date:  2015-03-24       Impact factor: 22.113

10.  A critical role for Apc in hematopoietic stem and progenitor cell survival.

Authors:  Zhijian Qian; Lina Chen; Anthony A Fernald; Bart O Williams; Michelle M Le Beau
Journal:  J Exp Med       Date:  2008-08-25       Impact factor: 14.307
View more
  6 in total

1.  Inhibition of WNT signaling in the bone marrow niche prevents the development of MDS in the Apcdel/+ MDS mouse model.

Authors:  Angela Stoddart; Jianghong Wang; Chunmei Hu; Anthony A Fernald; Elizabeth M Davis; Jason X Cheng; Michelle M Le Beau
Journal:  Blood       Date:  2017-03-27       Impact factor: 22.113

2.  Retroviral insertional mutagenesis identifies the del(5q) genes, CXXC5, TIFAB and ETF1, as well as the Wnt pathway, as potential targets in del(5q) myeloid neoplasms.

Authors:  Angela Stoddart; Zhijian Qian; Anthony A Fernald; Rachel J Bergerson; Jianghong Wang; Theodore Karrison; John Anastasi; Elizabeth T Bartom; Aaron L Sarver; Megan E McNerney; David A Largaespada; Michelle M Le Beau
Journal:  Haematologica       Date:  2016-03-04       Impact factor: 9.941

Review 3.  Therapy-related myeloid neoplasms: when genetics and environment collide.

Authors:  Megan E McNerney; Lucy A Godley; Michelle M Le Beau
Journal:  Nat Rev Cancer       Date:  2017-08-24       Impact factor: 60.716

4.  β-Catenin Is a Candidate Therapeutic Target for Myeloid Neoplasms with del(5q).

Authors:  Liping Li; Yue Sheng; Wenshu Li; Chao Hu; Nupur Mittal; Kaoru Tohyama; Amber Seba; You-Yang Zhao; Howard Ozer; Tongyu Zhu; Zhijian Qian
Journal:  Cancer Res       Date:  2017-06-13       Impact factor: 12.701

5.  Therapy-related myeloid neoplasms in 109 patients after radiation monotherapy.

Authors:  Anand Ashwin Patel; Alexandra E Rojek; Michael W Drazer; Howard Weiner; Lucy A Godley; Michelle M Le Beau; Richard A Larson
Journal:  Blood Adv       Date:  2021-10-26

6.  Cytotoxic Therapy-Induced Effects on Both Hematopoietic and Marrow Stromal Cells Promotes Therapy-Related Myeloid Neoplasms.

Authors:  Angela Stoddart; Jianghong Wang; Anthony A Fernald; Elizabeth M Davis; Camille R Johnson; Chunmei Hu; Jason X Cheng; Megan E McNerney; Michelle M Le Beau
Journal:  Blood Cancer Discov       Date:  2020-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.